FEB. 11-17, 2022
Eli Lilly and Co. has high hopes for donanemab, its new experimental drug for Alzheimer’s disease and a potential blockbuster for the pharma giant. But John Russell reports that its prospects have dimmed recently with a draft policy from the Centers for Medicare and Medicaid Services that would restrict reimbursement payments for the drug. Also in this week’s paper, Emily Ketterer reports that Indiana lawmakers are working to set up the first regulatory framework for utilities to build charging stations for electric vehicles. And Dave Lindquist fleshes out the plan for Hi & Mighty craft distillery to open at the Indiana State fairgrounds as its first year-round retail tenant in two decades.